Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective?
Statins reduce serum cholesterol and cardiovascular morbidity and mortality. The mechanisms for these beneficial effects are reviewed. Altered inflammatory responses and improved endothelial function mediated by statins are thought to be partly responsible for the reduction of morbidity and mortality as a result of cardiovascular events. In analogy, whether statins confer similar benefits on the kidney has not been established. This review critically considers the available data whereby dyslipidemia mediates renal dysfunction by modulating the inflammatory response to diverse cytokines. Also reviewed is the emerging database indicating that statins may modulate renal function by altering the response of the kidney to dyslipidemia.
Campese
Vito M
VM
Division of Nephrology, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA. campese@usc.edu
Nadim
Mitra K
MK
Epstein
Murray
M
D003324:Coronary Artery Disease / Q000517:prevention & control*; D016207:Cytokines / Q000187:drug effects* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000175:diagnosis / Q000188:drug therapy*; D007674:Kidney Diseases / Q000517:prevention & control; D007676:Kidney Failure, Chronic / Q000517:prevention & control* / Q000601:surgery; D007677:Kidney Function Tests; D016030:Kidney Transplantation; D008297:Male; D011379:Prognosis; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D016896:Treatment Outcome
D016207:Cytokines; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors